238results about "DsDNA viruses" patented technology

The present application relates to a kind of HSV-2 three antigen tandem recombinant protein vaccine compositions and its application, belong to the field of biotechnology.The vaccine composition includes antigen and composite adjuvant, antigen is HSV-2 gC2-gD2-gE2 three antigen tandem recombinant protein, composite adjuvant is CpG oligonucleotide and aluminum adjuvant;Wherein, HSV-2 gC2-gD2-gE2 three antigen tandem recombinant protein amino acid sequence as shown in SEQ ID NO.1, nucleotide sequence as shown in SEQ ID NO.2.The present application greatly reduces the time cost and economic cost in the process of protein preparation, compared with the original trivalent combination vaccine, it can induce the specific antibody level and neutralizing virus ability of mouse generation does not occur reduction, which provides a kind of new idea for developing advanced multi-target antigen HSV-2 virus vaccine, also provides a kind of safe and effective HSV-2 virus candidate vaccine.

Methods are disclosed for producing high-titer recombinant adeno-associated virus (rAAV) using a modified adenovirus-based helper nucleic acid. One aspect provided herein is a human adenovirus 5 (hAd)-based nucleic acid that does not contain one or more of (a) an E4 region having E4-ORF6 / 7, (b) a viral associated (VA) RNA region, (c) an E2A region having L4-22K and L4-33K, (d) at least one packaging protein, (e) at least one structural protein, (f) a major late promoter (MLP), (g) an E1 region, and / or (h) an E3 region.

Oncolytic viruses encoding recombinant TGF-β engineered to prevent homodimerization and recruitment of TGF-β receptor I are described. The engineered TGF-β minimonomer functions as a dominant-negative TGF-β inhibitor. Oncolytic viruses encoding TGF-β minimonomers can be used for cancer immunotherapy to inhibit the immunosuppressive tumor microenvironment. Provided are oncolytic viruses encoding recombinant TGF-β monomers, such as human recombinant TGF-β monomers.

The present disclosure generally relates to a viral vector carrying a synthetic cancer antigen and a chemokine. Also provided herein are compositions and uses of the viral vector for delivering, such as tagging, a tumor with the synthetic cancer antigen.

The present invention provides recombinant viral vectors that contain and express antigens of avian pathogens, compositions comprising the recombinant viral vectors, polyvalent vaccines comprising the recombinant viral vectors. The present invention further provides methods of vaccination against a variety of avian pathogens and method of producing the recombinant viral vectors.

The present invention relates to the field of genetic engineering, genetics and biotechnology. More specifically, the present invention relates to variants of a modified sequence of the adenovirus E2a gene, to a helper plasmid comprising the variants of the modified sequence of the adenovirus E2a gene for producing vectors based on adeno-associated virus, and to the use of the variants of the modified sequence of the adenovirus E2a gene and of the helper plasmids comprising these sequences for producing vectors based on adeno-associated viruses.

Disclosed herein is a chimeric nucleic acid including a human telomerase reverse transcriptase (hTERT) enhancer or a fragment thereof and an SV40 enhancer or a fragment thereof and methods of using the same.

The present disclosure provides methods and systems for targeting cell with mutations.

Systems and methods are provided that allow for the determination and prediction of payload toxicity in therapeutic viruses. Disclosed herein are methods of determining payload toxicity of a polypeptide expressed in a cell, the methods comprising: generating or obtaining a plurality of expression vectors, each expression vector comprising a different recombinant nucleic acid sequence encoding a corresponding recombinant polypeptide; expressing the recombinant nucleic acid sequence in a plurality of host cells while the host cells are in culture; sequencing the plurality of expression vectors after the host cells are in culture; and correlating at least a portion of the recombinant nucleic acid sequence with a measure of toxicity.

Provided herein is a conditionally-replicating serotype 5 adenovirus or adenoviral vector expressing a mutant E1A protein under control of a promoter that is responsive to hypoxia and inflammation and one or more immune modulators under control of a tumor-specific promoter. The adenovirus or adenoviral vector also comprises serotype 3 fiber domain. Also provided is a method of inducing cytotoxicity in tumor cells using a composition containing the adenovirus or adenoviral vector.

Recombinant polynucleotides and vectors containing an engineered (artificial) exon-intron-exon gene structure in a transgene are provided, which undergoes splicing when it is expressed in a target cell.

The present disclosure relates to compositions and methods for increasing the level of Klotho in a cell or in a subject and in particular to compositions and methods for treating diseases or conditions associated with Klotho. The methods described herein involve supplementing the level of Klotho protein in a cell by administering to the cell a nucleic acid encoding the Klotho protein.

Multiantigenic human papillomavirus (HPV) molecular vaccine constructs for use and treatment of HPV-related disorders and conditions, e.g., HPV molecular vaccines targeting HPV6 and HPV11-associated recurrent respiratory papillomatosis (RRP).

In one aspect, the present disclosure provides a method for producing various virus-derived construct plasmids from starting plasmids (for example, virus-derived construct plasmids of the present disclosure). In one embodiment, a method for producing virus-derived construct plasmids of the present disclosure includes a step of preparing a set of starting plasmids containing at least of a part of nucleic acid sequences required to construct a virus-derived construct, the set of starting plasmids including a set of corresponding alternative unit nucleic acids, and the set of corresponding alternative unit nucleic acids including at least one set of corresponding alternative unit nucleic acids containing different nucleic acid sequences; a step of treating the set of starting plasmids with a restriction enzyme and preparing a mixed solution containing cleaved alternative unit nucleic acid fragments; a step of ligating the cleaved alternative unit nucleic acid fragments to form an integrated nucleic acid; and a step of bringing the integrated nucleic acid into contact with a transformed organism to form virus-derived construct plasmids.

The present invention relates to a transformation and construction method of a plasmid expression vector based on a Tac promoter, in which a Shine-Dalgarno (SD) sequence of the plasmid expression vector is replaced and a tag sequence is further knocked out, a use of such constructed expression vector in the expression of recombinant exogenous proteins, especially in the expression of human papillomavirus L1 antigen protein, and a use of the human papillomavirus L1 antigen protein expression product in the prevention of cervical cancer.

Provided herein are recombinant nucleic acids comprising one or more polynucleotides encoding a laminin polypeptide and / or a filaggrin polypeptide; viruses comprising the recombinant nucleic acids; compositions and formulations comprising the recombinant nucleic acids and / or viruses; methods of their use; and articles of manufacture or kits thereof.

To provide an oncolytic virus for use in improved treatment of cancer through improved direct oncolytic effects, viral replication and spread through tumors.SOLUTION: The present invention provides an oncolytic virus comprising: (i) a fusogenic protein-encoding gene; and (ii) an immune stimulatory molecule-encoding gene and also provides a pharmaceutical composition comprising a virus and a pharmaceutically acceptable carrier or diluent.SELECTED DRAWING: None

The present invention relates to means and methods to prevent and / or treat Epstein-Barr virus (EBV) and EBV-induced diseases, such as EBV infection, infectious mononucleosis (IM), malignant or non-malignant post-transplant lymphoproliferative disorder (PTLD) and other EBV-associated diseases. In particular, the invention provides a SQAPLPCVL peptide that can be used in a treatment or a method of treatment to induce an EBV-specific immune response in a subject. The SQAPLPCVL can be used in a treatment or method of treatment as a vaccine against EBV and EBV-induced diseases. It is preferred herein that Epstein-Barr virus (EBV) and / or EBV-induced diseases are prevented.

The present disclosure provides orthogonal chimeric cytokine receptor / orthogonal cytokine pairs and compositions and methods for modified immune cells or precursors thereof (e.g., modified T cells) comprising an orthogonal chimeric cytokine receptor (e.g., an oIL2R-IL9R chimeric receptor) and a chimeric antigen receptor (CAR) or a T cell receptor (TCR). The present disclosure further provides an oncolytic adenoviral vector comprising a nucleic acid sequence encoding an orthogonal cytokine (e.g., oIL2), as well as methods of using the modified cells and the vector for treating cancer in a subject in need thereof.

The present invention relates to an oncolytic virus co-expressing the complement regulatory proteins CD55 and CD59. The oncolytic virus of the present invention maintains efficacy even upon intravenous injection, and thus, it may be applied to the therapy for various solid carcinomas and metastatic cancers as well as superficial solid cancers. In addition, the oncolytic virus of the present invention acquires resistance to the attack of human complement system by expressing a complement regulatory protein on the surface of the virus, and thus, it is stable in blood, and it maintains stable oncolytic activity upon intravenous injection, and thus, it may reduce the dose of the virus to minimize adverse effects of anticancer agents. Therefore, the oncolytic virus of the present invention may be advantageously used for prevention or treatment of cancer.

The presently disclosed subject matter relates to tumor infiltrated T cells induced by oncolytic virus ("OV-induced T cells"), methods of making and using said OV-induced T cells for an adoptive T-cell therapy. The presently disclosed subject matter further relates to oncolytic viruses and armed oncolytic viruses, methods of making and using said oncolytic viruses, as well as pharmaceutical compositions and kits comprising said oncolytic viruses.

The present invention relates to compositions and methods for treating wounds, conditions, and diseases of the skin. In particular, the present invention relates, in part, to pharmaceutical compositions comprising one or more polynucleotides suitable for enhancing, increasing, augmenting, and / or potentiating levels of collagen alpha-1 (VII) chain polypeptide and / or lysyl hydroxylase 3 polypeptide and / or keratin type I cytoskeletal 17 polypeptide in a subject. The present invention also relates, in part, to pharmaceutical compositions and methods for providing prophylactic, palliative, or therapeutic relief of a wound, condition, or disease of the skin in a subject, including a subject having or at risk of developing one or more symptoms of epidermolysis bullosa.